Please login to the form below
ceftazidime
This page shows the latest ceftazidime news and features for those working in and with pharma, biotech and healthcare.
NHS launches plans to expand drug contracts to develop new life-saving antibiotics
The new antibiotics, Shionogi’s Cefiderocol and Pfizer’s ceftazidime-avibactam, were awarded world-first subscription contracts, providing the drug-makers with fixed annual fees based primarily on the availability of
Latest news
-
Shionogi Europe and NHS England agree on antibiotic subscription model
exist. Fetcroja is one of two antimicrobial products – the other being Zavicefta (ceftazidime-avibactam), manufactured by Pfizer – to be selected and made available under the scheme run by NICE and NHS
-
NHS to offer two new treatments for drug-resistant superbugs as part of a new subscription-style payment plan
NHS England, the National Institute for Health and Care Excellence (NICE) and the UK Department of Health have concluded an assessment of Pfizer’s Zavicefta (ceftazidime with avibactam) and Shionogi’s
-
Allergan’s Avycaz breaks Gram-negative pneumonia antibiotic drought
Originally developed by Actavis (which was acquired by Allergan in a $25bn deal in 2014), Avycaz combines established cephalosporin antibiotic ceftazidime with avibactam, a novel beta lactamase inhibitor that helps tackle
-
Pfizer launches new antibiotic Zavicefta in UK and Germany
The European Medicines Agency (EMA) cleared Zavicefta (ceftazidime and avibactam) for the treatment of complicated Gram-negative bacterial infections requiring hospitalisation last year.
-
AZ slims down again with sale of antibiotics to Pfizer
The deal includes the approved antibiotics Merrem (meropenem), Zinforo (ceftaroline fosamil) and just-licensed Zavicefta (ceftazidime/avibactam), as well as two injectable antibiotic candidates - Allergan-partnered ATM-AVI (aztreonam/avibactam) and
More from news
Approximately 2 fully matching, plus 13 partially matching documents found.
Latest Intelligence
-
Deal Watch August 2016
14, 000. AstraZeneca (UK) antibiotic business. Pfizer (US). Asset acquisition. EU approved ceftazidime-avibactam), marketed meropenem and ceftaroline fosamil and clinical development assets aztreonam-avibactam (ATM-AVI) and CXL.
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
- World AIDS Day 35: Medscape’s Commitment to the Elimination of HIV through Education and Looking Towards the Future
- No “White Space” Between Live Meetings; the top 10 benefits of virtual advisory boards
- Building trust with HCPs: 6 takeaways from our industry webinar
- Eli Lilly and PRISM BioLab enter drug discovery collaboration worth over $660m
- NHS to offer stem cell transplants to patients living with rare blood disorder
- First WHO Global Clinical Trial Forum develops joint vision to improve clinical research
No results were found
PMHub
Branding Science
We are Branding Science Partners in thinking which inspires change in healthcare Branding Science are an award-winning global pharmaceutical market...
Latest intelligence
- Millennials: the wellness generation
- Looking at the results from a global healthcare research study focusing on the patients of the future...
- The problem with clinical trials (and how virtual insight-gathering can help)
- While still the gold standard of research, clinical trials are often riddled with issues that limit their applicability to broader populations or delay market access....
- The rise of digital healthcare – fuelled by open innovation in healthtech hubs
- How the ever-increasing uptake of digital solutions is enhancing patient engagement, increasing access to care and lowering the cost of drug development...
